For young stroke survivors, bleeding risk may outpace the risk of another stroke

A new study published in JAMA Network Open flips the script on how we think about long-term stroke prevention in younger patients. Researchers following over 1,200 Dutch adults aged 18–49 who survived a first ischemic stroke or TIA found that, over time, the risk of a serious bleeding event actually overtook the risk of having another stroke or vascular event.

The study tracked patients for a median of 4.2 years. Most were on antiplatelet therapy at discharge, with a smaller group on oral anticoagulants. Bleeding risk crossed the recurrent vascular event threshold at 6 years for antiplatelet users and as early as 5 years for those on oral anticoagulants.

By the Numbers:

• 10.7% — estimated 5-year cumulative bleeding risk
• 2.5 events per 100 patient-years — overall bleeding incidence
• Oral anticoagulant users bled at more than double the rate of antiplatelet users (5.2 vs. 2.3 events per 100 person-years)
• Women had 3.39x higher bleeding risk, largely driven by gynecologic bleeding
• Only 6.2% of bleeds were classified as major; no deaths were attributed to bleeding

Why it matters: For clinicians managing young stroke survivors, these findings are a reminder that long-term antithrombotic therapy carries real trade-offs over time. Regularly reassessing the bleeding vs. clot risk balance — especially in women and those on anticoagulants — could meaningfully shape treatment decisions.